Pacchetti C, Martignoni E, Bruggi P, Godi L, Aufdembrinke B, Miltenburger C, Voet B, Nappi G
Department of Neurology, Parkinson's Disease Centre, IRCCS C. Mondino, University of Pavia, Italy.
Mov Disord. 1993 Oct;8(4):463-5. doi: 10.1002/mds.870080408.
Terguride (TER), a semisynthetic derivative of lisuride, has been found to display dopamine (DA) agonist and DA antagonist effects in animals, depending on the experimental model used. TER (2 mg/day) was compared to placebo in 41 fluctuating Parkinson's disease patients to test its effect on akinesia and dyskinesia. Mean hours "off" decreased at weeks 6 and 12 (p < 0.05) in the TER group but the overall difference from the placebo group was not significant. Only the TER group displayed a decrease over time in mean Columbia University Rating Scale total score "on" and "off" (p = 0.001 and p = 0.03, respectively). Duration of involuntary movements and resulting disability were not significantly different between patients on TER and those on placebo administration. In the overall evaluation, patients preferred TER (p = 0.01). Tolerance of TER was very good in all but one patient whose wearing-off increased; no one dropped out because of side effects. This 3-month double-blind study showed that TER, added to stable doses of L-dopa, may have slight antiparkinsonian efficacy.
泰舒达（TER）是麦角乙脲的半合成衍生物，根据所使用的实验模型，已发现其在动物体内表现出多巴胺（DA）激动剂和DA拮抗剂的作用。在41例症状波动的帕金森病患者中，将TER（2毫克/天）与安慰剂进行比较，以测试其对运动不能和异动症的影响。TER组在第6周和第12周时“关”期的平均小时数减少（p < 0.05），但与安慰剂组的总体差异不显著。只有TER组“开”期和“关”期的哥伦比亚大学评定量表总分随时间下降（分别为p = 0.001和p = 0.03）。服用TER的患者与服用安慰剂的患者之间，不自主运动的持续时间和由此导致的残疾情况没有显著差异。在总体评估中，患者更倾向于TER（p = 0.01）。除一名患者的症状波动增加外，其他所有患者对TER的耐受性都非常好；没有人因副作用而退出。这项为期3个月的双盲研究表明，在稳定剂量的左旋多巴基础上加用TER可能具有轻微的抗帕金森病疗效。
